>>Signaling Pathways>> Others>>KMH-233

KMH-233

Catalog No.GC61845

KMH-233은 강력하고 가역적이며 선택적인 l형 아미노산 수송체 1(LAT1) 억제제로 LAT1 기질인 l-류신(IC50=18μM)의 흡수와 세포 성장을 억제합니다. KMH-233은 낮은 농도(25μM)에서도 베스타틴과 시스플라틴의 효능을 크게 강화합니다.

Products are for research use only. Not for human use. We do not sell to patients.

KMH-233 Chemical Structure

Cas No.: 1941174-13-5

Size 가격 재고 수량
5 mg
US$1,305.00
재고 있음
10 mg
US$2,205.00
재고 있음
25 mg
US$4,365.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

KMH-233, a potent, reversible and selective l-type amino acid transporter 1 (LAT1) inhibitor, inhibits the uptake of LAT1 substrate, l-leucin (IC50=18 µM) as well as cell growth. KMH-233 significantly potentiates the efficacy of Bestatin and Cisplatin even at low concentrations (25 µM)[1].

KMH-233 is able to inhibit binding and transport of essential neutral amino acids and thus, inhibit the cell growth of cancer cells[1].KMH-233 shows a significant reduction of cell growth with an IC50 of 124 µM[1].KMH-233 is effective and able to potentiate the anti-proliferative efficacy of Bestatin (100 µM) and Cisplatin (100 µM) at a lower concentration of 25 µM, inhibiting cell growth 53% and 50%, respectively[1].

References:
[1]. Huttunen KM, et al. A Selective and Slowly Reversible Inhibitor of l-Type Amino Acid Transporter 1 (LAT1) Potentiates Antiproliferative Drug Efficacy in Cancer Cells. J Med Chem. 2016;59(12):5740-5751.

리뷰

Review for KMH-233

Average Rating: 5 ★★★★★ (Based on Reviews and 19 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for KMH-233

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.